Management of Abemaciclib‐Associated Adverse Events in Patients with Hormone Receptor‐Positive, Human Epidermal Growth Factor Receptor 2‐Negative Advanced Breast Cancer: Safety Analysis of MONARCH 2 and MONARCH 3

অনুরূপ উপাদানগুলি

• Management of Abemaciclib‐Associated Adverse Events in Patients with Hormone Receptor‐Positive, Human Epidermal Growth Factor Receptor 2‐Negative Advanced Breast Cancer: Safety Analysis of MONARCH 2 and MONARCH 3
  অনুযায়ী: Rugo, Hope S., অন্যান্য
  প্রকাশিত: (2020)
• In Reply
  অনুযায়ী: Rugo, Hope S., অন্যান্য
  প্রকাশিত: (2021)
• MONARCH 3 final PFS: a randomized study of abemaciclib as initial therapy for advanced breast cancer
  অনুযায়ী: Johnston, Stephen, অন্যান্য
  প্রকাশিত: (2019)
• The Effect of Abemaciclib Plus Fulvestrant on Overall Survival in Hormone Receptor–Positive, ERBB2-Negative Breast Cancer That Progressed on Endocrine Therapy—MONARCH 2: A Randomized Clinical Trial
  অনুযায়ী: Sledge, George W., অন্যান্য
  প্রকাশিত: (2019)
• Abemaciclib as initial therapy for advanced breast cancer: MONARCH 3 updated results in prognostic subgroups
  অনুযায়ী: Johnston, Stephen, অন্যান্য
  প্রকাশিত: (2021)